The developers claim that six months of patented 40 Hz gamma sensory stimulation can reduce white matter atrophy in Alzheimer’s patients, as well as protect axons and possibly prevent damage to myelin and oligodendrocytes.
Cognito Therapeutics plans to begin trials earlier this year to confirm the device’s clinical efficacy.
Source: Ferra
